The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 13, 2016

Filed:

May. 24, 2011
Applicants:

Byung Chul Lee, Seoul, KR;

Sang Eun Kim, Seoul, KR;

Ji Sun Kim, Anyang-si, KR;

Byung Seok Moon, Seoul, KR;

Jae Ho Jung, Seoul, KR;

Inventors:

Byung Chul Lee, Seoul, KR;

Sang Eun Kim, Seoul, KR;

Ji Sun Kim, Anyang-si, KR;

Byung Seok Moon, Seoul, KR;

Jae Ho Jung, Seoul, KR;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 51/00 (2006.01); A61M 36/14 (2006.01); A61K 51/08 (2006.01); C07K 7/64 (2006.01); G01N 33/574 (2006.01); G01N 33/60 (2006.01);
U.S. Cl.
CPC ...
A61K 51/088 (2013.01); A61K 51/082 (2013.01); C07K 7/64 (2013.01); G01N 33/574 (2013.01); G01N 33/60 (2013.01);
Abstract

The present invention relates to tricarbonyl technetium-99m or rhenium-188 labeled cyclic RGD derivatives, a preparation method thereof, and a pharmaceutical composition containing the derivative as an active ingredient for use in the diagnosis or treatment (radiotherapy) of angiogenesis-related diseases. The tricarbonyl technetium-99m or rhenium-188 labeled cyclic RGD derivatives of the present invention has a high subnanomolar affinity to integrin αβ(also called as a vitronectin receptor) that is activated in an angiogenic action induced by a tumor, and acts exclusively upon cancer cells having selectively activated integrin αβbecause of a substantially low intake into the liver and intestines.


Find Patent Forward Citations

Loading…